The Hematologist

banner image

Another Myth About Sickle Cell Trait Bites the Dust

Dr. DeBaun reviews studies that debunk the misconception that sickle cell trait is associated with common medical morbidities.

Read more
banner image

VTE Guidelines Podcast

Part 1 of this podcast features Drs. Cuker and Schünemann, and Part 2 includes Drs. Cushman and Monagle discussing the ASH Guidelines on VTE, specifically two now open for public comment.

Play here
banner image

Tranexamic Acid

Dr. Linkins reviews the WOMAN study, which proves the usefulness of tranexamic acid to reduce maternal mortality due to postpartum hemorrhage.

Read more
Current Issue Static Feature

Current Issue

July/August 2017              
Volume 14, Issue 4

Read current issue

President's Column

Presidents Column - Kenneth AndersonKraft Family Professor of Medicine, Harvard Medical School; Director Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center Dana-Farber Cancer Institute, Boston, MA
Beyond Business As Usual
July 1, 2017

Dr. Kenneth Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Execxutive Committee Spring Retreat in Canada.

View all president's column articles

  • Congress Changes Stance on ACA Repeal and Replace
    July 24, 2017

    On July 13, 2017, the U.S. Senate released an updated version of the Better Care Reconciliation Act (BCRA), legislation to repeal large provisions of the Affordable Care Act (ACA).

  • DEA Eliminates Grace Period for Registration Renewal
    December 21, 2016

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model
    December 20, 2016

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells
    November 23, 2016

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

View all Policy News